Avandia Given Positive Reviews Due to $$$$$?
And so the Avandia saga continues. A recent analysis of articles and reviews about the type 2 diabetes drug manufactured by drug giant, GlaxoSmithKline, indicates that experts who were paid by Glaxo consistently gave more positive reviews concerning the drug’s efficacy and safety than those not paid by Glaxo. Hundreds of studies have been performed in the last three years, many arriving at very different conclusions regarding this very popular drug.
The New England Journal of Medicine, in 2007, published an article indicating that the use of Avandia was “associated with a significant increase in the risk of heart attack.” Shortly after the publication of this article, the FDA issued a black box warning and recommended that Glaxo take the dangerous drug off the market.
In response to the allegation that Avandia is receiving positive reviews based on money being paid to those reviewing the drug, Mary Anne Rhyne, Glaxo spokeswoman, said GSK “will disclose research payments made to health care professionals and their institutions” beginning next year; the disclosures will cover all research studies that began on January 1, 2010.
If you or a loved one has taken Avandia and has suffered adverse cardiac events because of it, please contact the defective drug attorneys at Schlichter, Bogard & Denton, serving Little Rock, Arkansas and all of the U.S., today to schedule a confidential consultation.